Literature DB >> 24038035

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Imke H Bartelink1, Rada M Savic, Julia Mwesigwa, Jane Achan, Tamara Clark, Albert Plenty, Edwin Charlebois, Moses Kamya, Sera L Young, Monica Gandhi, Diane Havlir, Deborah Cohan, Francesca Aweeka.   

Abstract

Pregnancy and food insecurity may impact antiretroviral (ART) pharmacokinetics (PK), adherence and response. We sought to quantify and characterize the PK of lopinavir/ritonavir (LPV/r) and efavirenz (EFV) by pregnancy and nutritional status among HIV-infected women in Tororo, Uganda. In 2011, 62/225 ante-partum/post-partum single dried blood spot samples DBS and 43 post-partum hair samples for LPV/r were derived from 116 women, 51/194 ante-/post-partum DBS and 53 post-partum hair samples for EFV from 105 women. Eighty percent of Ugandan participants were severely food insecure, 26% lost weight ante-partum, and median BMI post-partum was only 20.2 kg/m(2) . Rich PK-data of normally nourished (pregnant) women and healthy Ugandans established prior information. Overall, drug exposure was reduced (LPV -33%, EFV -15%, ritonavir -17%) compared to well-nourished controls (P < 0.001), attributable to decreased bioavailability. Pregnancy increased LPV/r clearance 68% (P < 0.001), whereas EFV clearance remained unchanged. Hair concentrations correlated with plasma-exposure (P < 0.001), explaining 29% PK-variability. In conclusion, pregnancy and food insecurity were associated with lower ART exposures in this cohort of predominantly underweight women, compared to well-nourished women. Much variability in plasma-exposure was quantified using hair concentrations. Addressing malnutrition as well as ART-PK in this setting should be a priority.
© 2013, The American College of Clinical Pharmacology.

Entities:  

Keywords:  clinical research (CRE); infectious diseases (INF); pharmacodynamics (PDY); pharmacokinetics and drug metabolism; pharmacology (PHA)

Mesh:

Substances:

Year:  2013        PMID: 24038035      PMCID: PMC3933454          DOI: 10.1002/jcph.167

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  69 in total

1.  Nutrition and pharmacology: general principles and implications for HIV.

Authors:  Daniel J Raiten
Journal:  Am J Clin Nutr       Date:  2011-11-16       Impact factor: 7.045

2.  Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.

Authors:  Wiete Kromdijk; Jan W Mulder; Hilde Rosing; Patrick M Smit; Jos H Beijnen; Alwin D R Huitema
Journal:  J Antimicrob Chemother       Date:  2012-02-01       Impact factor: 5.790

3.  Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.

Authors:  Gert Uves van Zyl; Thijs E van Mens; Helen McIlleron; Michele Zeier; Jean B Nachega; Eric Decloedt; Carolina Malavazzi; Peter Smith; Yong Huang; Lize van der Merwe; Monica Gandhi; Gary Maartens
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

4.  Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.

Authors:  Tim R Cressey; Alice Stek; Edmund Capparelli; Chureeratana Bowonwatanuwong; Sinart Prommas; Pannee Sirivatanapa; Prapap Yuthavisuthi; Chanon Neungton; Yanling Huo; Elizabeth Smith; Brookie M Best; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2012-03-01       Impact factor: 3.731

Review 5.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

6.  Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

Authors:  Jintanat Ananworanich; Pope Kosalaraksa; Andrew Hill; Umaporn Siangphoe; Alina Bergshoeff; Chitsanu Pancharoen; Chulapan Engchanil; Kiat Ruxrungtham; David Burger
Journal:  Pediatr Infect Dis J       Date:  2005-10       Impact factor: 2.129

7.  Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

Authors:  Brookie M Best; Alice M Stek; Mark Mirochnick; Chengcheng Hu; Hong Li; Sandra K Burchett; Steven S Rossi; Elizabeth Smith; Jennifer S Read; Edmund V Capparelli
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

8.  Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women.

Authors:  Saurabh Mehta; Karim P Manji; Alicia M Young; Elizabeth R Brown; Charles Chasela; Taha E Taha; Jennifer S Read; Robert L Goldenberg; Wafaie W Fawzi
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

9.  Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

Authors:  Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Anton Pozniak; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Phillippa Easterbrook; Sara Gibbons; Saye Khoo
Journal:  Antivir Ther       Date:  2008

10.  Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.

Authors:  Daniel González de Requena; Francisco Blanco; Teresa Garcia-Benayas; Inmaculada Jiménez-Nácher; Juan González-Lahoz; Vincent Soriano
Journal:  AIDS Patient Care STDS       Date:  2003-09       Impact factor: 5.078

View more
  33 in total

1.  Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Authors:  Nhi Phung; Karen Kuncze; Hideaki Okochi; Alexander Louie; Leslie Z Benet; Igho Ofokotun; David W Haas; Judith S Currier; Tariro D Chawana; Anandi N Sheth; Peter Bacchetti; Monica Gandhi; Howard Horng
Journal:  Rapid Commun Mass Spectrom       Date:  2018-03-15       Impact factor: 2.419

2.  Efavirenz pharmacokinetics during pregnancy and infant washout.

Authors:  Regis Kreitchmann; Stein Schalkwijk; Brookie Best; Jiajia Wang; Angela Colbers; Alice Stek; David Shapiro; Tim Cressey; Mark Mirochnick; David Burger
Journal:  Antivir Ther       Date:  2019

Review 3.  Food insecurity, sexual risk behavior, and adherence to antiretroviral therapy among women living with HIV: A systematic review.

Authors:  Elisabeth Chop; Avani Duggaraju; Angela Malley; Virginia Burke; Stephanie Caldas; Ping Teresa Yeh; Manjulaa Narasimhan; Avni Amin; Caitlin E Kennedy
Journal:  Health Care Women Int       Date:  2017-06-06

Review 4.  Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.

Authors:  Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

5.  The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Authors:  Imke H Bartelink; Rada M Savic; Grant Dorsey; Theodore Ruel; David Gingrich; Henriette J Scherpbier; Edmund Capparelli; Vincent Jullien; Sera L Young; Jane Achan; Albert Plenty; Edwin Charlebois; Moses Kamya; Diane Havlir; Francesca Aweeka
Journal:  Pediatr Infect Dis J       Date:  2015-03       Impact factor: 2.129

6.  <i>Chuma na Uchizi</i>: A Livelihood Intervention to Increase Food Security of People Living with HIV in Rural Zambia.

Authors:  Rainier Masa; Gina Chowa; Victor Nyirenda
Journal:  J Health Care Poor Underserved       Date:  2018

7.  Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.

Authors:  Deborah Cohan; Paul Natureeba; Catherine A Koss; Albert Plenty; Flavia Luwedde; Julia Mwesigwa; Veronica Ades; Edwin D Charlebois; Monica Gandhi; Tamara D Clark; Bridget Nzarubara; Jane Achan; Theodore Ruel; Moses R Kamya; Diane V Havlir
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

8.  Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda.

Authors:  Peter K Olds; Julius P Kiwanuka; Denis Nansera; Yong Huang; Peter Bacchetti; Chengshi Jin; Monica Gandhi; Jessica E Haberer
Journal:  AIDS Care       Date:  2014-12-06

9.  CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.

Authors:  Carola R Röhrich; Britt I Drögemöller; Ogechi Ikediobi; Lize van der Merwe; Nelis Grobbelaar; Galen E B Wright; Nathaniel McGregor; Louise Warnich
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205

10.  Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Authors:  Kelly E Dooley; Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; David W Haas; Jennifer Hull; Regina Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron
Journal:  J Infect Dis       Date:  2014-07-31       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.